A study to determine survival outcomes in non-small-cell lung cancers patients in real-life settings
Latest Information Update: 12 Oct 2021
At a glance
- Drugs Alectinib (Primary) ; Brigatinib (Primary) ; Crizotinib (Primary) ; Lorlatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Oct 2021 New trial record
- 14 Sep 2021 Results presented at the 2021 World Conference on Lung Cancer